Option Care Health (NASDAQ:OPCH - Get Free Report)'s stock had its "outperform" rating reaffirmed by analysts at Barrington Research in a research note issued to investors on Thursday,Benzinga reports. They presently have a $38.00 price target on the stock. Barrington Research's price objective would suggest a potential upside of 27.18% from the company's current price.
Several other equities analysts have also recently weighed in on the stock. JMP Securities reissued a "market outperform" rating and issued a $36.00 target price on shares of Option Care Health in a research note on Wednesday, June 18th. UBS Group raised shares of Option Care Health from a "neutral" rating to a "buy" rating and raised their target price for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.
Check Out Our Latest Research Report on Option Care Health
Option Care Health Stock Down 2.0%
Shares of OPCH traded down $0.61 during mid-day trading on Thursday, hitting $29.88. 1,042,047 shares of the company's stock were exchanged, compared to its average volume of 1,852,837. The company has a market cap of $4.89 billion, a PE ratio of 24.10, a P/E/G ratio of 1.81 and a beta of 0.73. Option Care Health has a 52 week low of $21.39 and a 52 week high of $35.53. The company has a 50-day simple moving average of $31.80 and a 200 day simple moving average of $31.42. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.54 and a quick ratio of 1.02.
Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The company had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.26 billion. Option Care Health had a net margin of 4.12% and a return on equity of 16.90%. The business's quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the business earned $0.26 EPS. On average, research analysts forecast that Option Care Health will post 1.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Option Care Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Option Care Health by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company's stock worth $448,118,000 after purchasing an additional 75,313 shares during the period. Wellington Management Group LLP boosted its position in Option Care Health by 84.6% during the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock worth $425,143,000 after purchasing an additional 8,400,208 shares during the period. Fuller & Thaler Asset Management Inc. boosted its position in Option Care Health by 30.8% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock worth $146,947,000 after purchasing an additional 989,048 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Option Care Health by 17.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock worth $92,518,000 after buying an additional 591,042 shares in the last quarter. Finally, Durable Capital Partners LP acquired a new stake in shares of Option Care Health during the first quarter worth $122,905,000. 98.05% of the stock is owned by institutional investors.
About Option Care Health
(
Get Free Report)
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
See Also

Before you consider Option Care Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Option Care Health wasn't on the list.
While Option Care Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.